Next Article in Journal
Oxidized Low-Density Lipoprotein-Deteriorated Psoriasis Is Associated with the Upregulation of Lox-1 Receptor and Il-23 Expression In Vivo and In Vitro
Previous Article in Journal
PpSARK Regulates Moss Senescence and Salt Tolerance through ABA Related Pathway
Previous Article in Special Issue
VEGF Upregulation in Viral Infections and Its Possible Therapeutic Implications
Article Menu
Issue 9 (September) cover image

Export Article

Open AccessReview
Int. J. Mol. Sci. 2018, 19(9), 2611; https://doi.org/10.3390/ijms19092611

The Use of Vascular Endothelial Growth Factor Inhibitors and Complementary Treatment Options in Polypoidal Choroidal Vasculopathy: A Subtype of Neovascular Age-Related Macular Degeneration

1
Singapore National Eye Centre, Singapore 168751, Singapore
2
Singapore Eye Research Institute, Singapore 169856, Singapore
3
Sydney Eye Hospital Foundation, Sydney Eye Hospital, Sydney 2000, Australia
4
The Save Sight Institute, Sydney Medical School, University of Sydney, Sydney 2000, Australia
*
Author to whom correspondence should be addressed.
Received: 13 July 2018 / Revised: 17 August 2018 / Accepted: 27 August 2018 / Published: 3 September 2018
(This article belongs to the Special Issue Vascular Endothelial Growth Factor)
Full-Text   |   PDF [2434 KB, uploaded 3 September 2018]   |  

Abstract

Polypoidal choroidal vasculopathy (PCV) is a subtype of neovascular age-related macular degeneration (AMD; nAMD) which occurs more commonly in Asian populations as compared to Caucasians. PCV and nAMD share pathological mechanisms, including pathological expression of vascular endothelial growth factor (VEGF). The advent of anti-vascular endothelial growth factor (VEGF) revolutionized the treatment of nAMD. Despite being a subtype of nAMD, PCV responds less well to VEGF inhibitors; thus, photodynamic therapy (PDT) in combination with anti-VEGF treatment may be considered. This review aims to summarize the current evidence for the treatment of PCV, especially whether VEGF inhibitors should be used alone or in combination with PDT. View Full-Text
Keywords: anti-VEGF; AMD; photodynamic therapy; polypoidal choroidal vasculopathy; PCV anti-VEGF; AMD; photodynamic therapy; polypoidal choroidal vasculopathy; PCV
Figures

Figure 1

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. (CC BY 4.0).
SciFeed

Share & Cite This Article

MDPI and ACS Style

Teo, K.Y.C.; Gillies, M.; Fraser-Bell, S. The Use of Vascular Endothelial Growth Factor Inhibitors and Complementary Treatment Options in Polypoidal Choroidal Vasculopathy: A Subtype of Neovascular Age-Related Macular Degeneration. Int. J. Mol. Sci. 2018, 19, 2611.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
Int. J. Mol. Sci. EISSN 1422-0067 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top